GlassScriptPhysician profile
Tonya Perkins
NPI 1033130497
$2,525.34
in general payments reported to CMS, 2019-2025
27 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $111 · 2022: $110 · 2023: $802 · 2024: $756 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.54 | 2023-2025 | |
| Lilly USA, LLC | $306.74 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $260.79 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $212.05 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $132.58 | 2023-2025 | |
| Glaxosmithkline, LLC. | $131.40 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $96.54 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $85.01 | 2020-2023 | Trintellix |
| Astellas Pharma US INC | $74.41 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $60.84 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.54 | 2019-2024 | Jardiance |
| Abbott Laboratories | $56.25 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $45.50 | 2024-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $42.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.05 | 2020-2024 | Gardasil 9, Gardasil |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $35.72 | 2024-2025 | Heplisav-B |
| Exact Sciences Corporation | $35.22 | 2023-2025 | Cologuard Collection Kit |
| Circassia INC. | $16.99 | 2019 | |
| Amarin Pharma, INC. | $16.51 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.99 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $15.36 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $15.17 | 2023 | Rexulti |
| Dexcom, INC. | $14.87 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $11.96 | 2019 | |
| Zyla Life Sciences, INC. | $11.67 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.43 | 2020 | |
| Genentech USA, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.